AllianceBernstein
AVDL

AllianceBernstein’s Avadel Pharmaceuticals AVDL Stock Holding History

AllianceBernstein’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-98,438
Closed -$2.12M – 3234
2025
Q4 		$2.12M Buy
98,438
+31,776
+48% +$617K ﹤0.01% 1962
2025
Q3 		$1.02M Sell
66,662
-30,376
-31% -$395K ﹤0.01% 2351
2025
Q2 		$48.9K Buy
97,038
+13,903
+17% +$122K ﹤0.01% 3210
2025
Q1 		$651K Sell
83,135
-13,575
-14% -$114K ﹤0.01% 2447
2024
Q4 		$1.02M Buy
96,710
+31,588
+49% +$384K ﹤0.01% 2319
2024
Q3 		$854K Sell
65,122
-36,102
-36% -$550K ﹤0.01% 2400
2024
Q2 		$322M Buy
+101,224
New +$1.65M 0.11% 151
2016
Q1 		– Sell
-876,002
Closed -$10.7M – 2912
2015
Q4 		$10.7M Buy
876,002
+87,882
+11% +$1.37M 0.01% 849
2015
Q3 		$12.9M Buy
+788,120
New +$17.4M 0.01% 819

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

AllianceBernstein's AVDL Position: Q1 2026 in Review

AllianceBernstein sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 98,438 shares — an estimated $2.12M sold.

AllianceBernstein first reported a position in AVDL in Q3 2015 and held it in 9 quarters. The position peaked at $322M in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • AllianceBernstein reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AllianceBernstein sold 98,438 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2.12M.
  • AllianceBernstein first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 9 quarters.
  • AllianceBernstein's Avadel Pharmaceuticals position peaked at $322M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.